Xeris Biopharma Holdings Inc
NASDAQ:XERS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Xeris Biopharma Holdings Inc
NASDAQ:XERS
|
US |
|
V
|
Vector Group Ltd
DUS:VGR
|
US |
|
M
|
MDxHealth SA
F:O6C0
|
BE |
|
C
|
CNH Industrial NV
SWB:37C
|
UK |
|
Credicorp Ltd
NYSE:BAP
|
PE |
|
B
|
Brainbees Solutions Ltd
NSE:FIRSTCRY
|
IN |
|
WANdisco PLC
LSE:WAND
|
UK |
|
U
|
Unilever Indonesia Tbk PT
XBER:UTG
|
ID |
|
Jiangsu Expressway Co Ltd
SSE:600377
|
CN |
|
B
|
Bank Negara Indonesia (Persero) Tbk PT
OTC:PBNNF
|
ID |
|
G
|
G1 Therapeutics Inc
F:G1H
|
US |
|
F
|
Ford Motor Co
DUS:FMC1
|
US |
|
Iss A/S
OTC:ISFFF
|
DK |
|
LEG Immobilien SE
OTC:LEGIF
|
DE |
|
Axway Software SA
F:1XV
|
FR |
|
Cooper Companies Inc
NASDAQ:COO
|
US |
Wall St Price Targets
XERS Price Targets Summary
Xeris Biopharma Holdings Inc
According to Wall Street analysts, the average 1-year price target for XERS is 11.51 USD with a low forecast of 8.08 USD and a high forecast of 18.9 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is XERS's stock price target?
Price Target
11.51
USD
According to Wall Street analysts, the average 1-year price target for XERS is 11.51 USD with a low forecast of 8.08 USD and a high forecast of 18.9 USD.
What is the Revenue forecast for Xeris Biopharma Holdings Inc?
Projected CAGR
10%
Over the last 8 years, the compound annual growth rate for Revenue has been 92%. The projected CAGR for the next 7 years is 10%.
What is the Gross Profit forecast for Xeris Biopharma Holdings Inc?
Projected CAGR
20%
Over the last 8 years, the compound annual growth rate for Gross Profit has been 88%. The projected CAGR for the next 5 years is 20%.
What is the Operating Income forecast for Xeris Biopharma Holdings Inc?
Projected CAGR
63%
The compound annual growth rate for Operating Income over the next 5 years is 63%.
What is the Pre-Tax Income forecast for Xeris Biopharma Holdings Inc?
Projected CAGR
517%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 517%.
What is the Net Income forecast for Xeris Biopharma Holdings Inc?
Projected CAGR
356%
The compound annual growth rate for Net Income over the next 4 years is 356%.
